alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 99(b)


        Written Statement of the Vice President Law/Finance and Secretary
                          Pursuant to 18 U.S.C. ss.1350

       Solely for the purposes of complying with 18 U.S.C. ss.1350, I, the
undersigned Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
"Company"), hereby certify, based on my knowledge, that the Quarterly Report on
Form 10-Q of the Company for the quarter ended June 30, 2002 (the "Report")
fully complies with the requirements of Section 13(a) of the Securities Exchange
Act of 1934, except that, for the reasons described in the Report, the Company's
independent public accountants have been unable to complete their review of the
unaudited consolidated financial statements included in the Report as required
by Rule 10-01(d) of Regulation S-X; and that information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operations of the Company.




 /s/  Wayne E. Larsen
----------------------------
Wayne E. Larsen
August 9, 2002
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1490 Lysozyme (muramidase) test system. ( a ) *Identification.* A lysozyme (muramidase) test system is a device intended to measure the activity of the bacteriolytic enzyme lysozyme (muramidase) in serum, plasma, leukocytes, and urine. Lysozyme measurements are used in the diagnosis and treatment of monocytic leukemia and kidney disease.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38788, July 25, 2001]
§ 820.184 Device history record. Each manufacturer shall maintain device history records (DHR's). Each manufacturer shall establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of this part. The DHR shall include, or refer to the location of, the following information: ( a ) The dates of manufacture;
( b ) The quantity manufactured;
( c ) The quantity released for distribution;
( d ) The acceptance records which demonstrate the device is manufactured in accordance with the DMR;
( e ) The primary identification label and labeling used for each production unit; and
( f ) Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used.
[61 FR 52654, Oct. 7, 1996, as amended at 78 FR 58822, Sept. 24, 2013]
Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Ambassadors International, Inc. (the Company) on Form 10-K for the year ended December 31, 2006 as filed with
the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Brian R. Schaefgen, Chief Financial Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                        |  |  |  | 
|----------------------- |  |  |  | 
|/s/ Brian R. Schaefgen  |  |  |  | 
|Brian R. Schaefgen      |  |  |  | 
|Chief Financial Officer |  |  |  | 
|March 16, 2007          |  |  |  | 

The foregoing certification is being furnished solely to accompany this Report pursuant to 18 U.S.C.
§1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.
Exhibit 10.3


AMENDMENT


THIS AMENDMENT is
made as of the 31st day of July 2006 to the Employment Agreement between Paul
A. Mahon (“Executive”) and United Therapeutics Corporation dated June 16, 2001,
as previously amended (the “Agreement”).


WHEREAS, the parties
desire to amend the Agreement as provided below.


NOW THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereby amend the Agreement as follows:


1.  Term of the Agreement.  The first sentence of Section
10(c) of the Agreement presently provides as follows:


Executive agrees not to accept employment from, nor
render services in any capacity for, nor have any other business relationships
with, nor engage in any business activity in which it would be useful or
helpful to Executive or others with whom he is associated for Executive to use
or disclose Confidential Information of the Company with, a person or entity
engaged in a business located anywhere in the world which directly competes with
the Company’s then existing or planned business a period of one (1) year
following Executive’s last receipt of compensation from the Company, whether
the termination of Executive’s employment by either party was with or without
Cause.


In order to increase the term of Executive’s non-competition agreement
with United Therapeutics Corporation, the foregoing first sentence of Section 10(c) shall be replaced in
its entirety with the following provision:


Executive agrees not to accept employment from, nor
render services in any capacity for, nor have any other business relationships
with, nor engage in any business activity in which it would be useful or
helpful to Executive or others with whom he is associated for Executive to use
or disclose Confidential Information of the Company with, a person or entity
engaged in a business located anywhere in the world which directly competes
with the Company’s then existing or planned business a period of two (2) years
following Executive’s last receipt of compensation from the Company, whether
the termination of Executive’s employment by either party was with or without
Cause.


2.  Effect.  No other provisions of the Agreement shall be
affected by this Amendment, and all other provisions of the Agreement shall
remain in full force and effect.


In
witness whereof, the parties have executed this Amendment effective as of the
date first written above.


 


	
  

  	
   

  	
  UNITED THERAPEUTICS
  CORPORATION

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  /s/ Paul A.
  Mahon

  	
   

  	
  /s/ Alyssa Friedrich

  	
   

  	
   

  
	
  Paul A. Mahon

  	
   

  	
  Alyssa Friedrich
EXHIBIT 23

               Consent of Independent Certified Public Accountants

The Board of Directors and
Stockholders of Porta Systems Corp.
Syosset, New York

      We hereby consent to the  incorporation  by reference in the  Prospectuses
constituting a part of the  Registration  Statements (Reg. No. 33-12146) on Form
S-8,  (Reg. No.  33-41992) on Form S-8, (Reg. No.  333-48839) on Form S-3, (Reg.
No.  333-68321) on Form S-8, and (Reg. No.  333-72369) on Form S-8 of our report
dated March 15, 2002, relating to the consolidated financial statements of Porta
Systems Corp. and subsidiaries  appearing in the Company's Annual Report on Form
10-K for the year ended  December 31, 2001.  Our report  contains an explanatory
paragraph regarding the Company's ability to continue as a going concern.

                                                    /s/ BDO Seidman, LLP

                                                      BDO SEIDMAN, LLP


Melville, New York
April 12, 2002
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
Pursuant to 18 U.S.C. Section 1350, as adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned, John P. Wilmers, Chief Executive Officer of Ballantyne Strong, Inc. (the "Company"), has executed this
certification in connection with the filing with the Securities and Exchange Commission of the Company's Annual Report on Form 10-K/A for the year ended December 31, 2009
(the "Report").

The
undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his knowledge
that:



IN
WITNESS WHEREOF, the undersigned has executed this certification as of the 23rd day of June, 2010.

/s/ JOHN P. WILMERS John P. Wilmers
Chief Executive Officer


A
signed original of this written statement required by Section 906 has been provided to Ballantyne Strong, Inc. and will be retained by Ballantyne Strong, Inc. and furnished to
the Securities and Exchange Commission or its staff upon request.

---



QuickLinks
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1255 2,3-Diphosphoglyceric acid test system. ( a ) *Identification.* A 2,3-diphosphoglyceric acid test system is a device intended to measure 2,3-diphosphoglyceric acid (2,3-DPG) in erythrocytes (red blood cells). Measurements of 2,3-diphosphoglyceric acid are used in the diagnosis and treatment of blood disorders that affect the delivery of oxygen by erythrocytes to tissues and in monitoring the quality of stored blood.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38787, July 25, 2001]
Exhibit 10.3(c)  


 Second Amendment to Consulting Agreement  


        This Second Amendment to Consulting Agreement (the "Second Amendment") is entered into as of December 10, 2002, by and between Cephalon, Inc., a
Delaware corporation ("Cephalon") and Martyn D. Greenacre ("Consultant"). 


        WHEREAS,
Cephalon and Consultant have previously entered into a Consulting Agreement (the "Consulting Agreement") dated as of October 1, 2001; 


        WHEREAS,
Cephalon and Consultant have previously amended the Consulting Agreement dated as of April 1, 2002 (the "Amendment") to extend the term through December 31, 2002; 


        WHEREAS,
it is deemed to be in the best interests of both parties that the Consulting Agreement continue beyond the December 31, 2002 expiration date. 



        NOW,
THEREFORE, in consideration of the mutual promises set forth herein, and intending to be bound legally hereby, Cephalon and Consultant hereby agree as follows: 


1.    Amendments.    The Consulting Agreement is hereby amended as follows, effective as of the date set forth above: 


1.1.    Section 2.    Section 2
is replaced in its entirety with the following language: "The term of this Agreement shall continue in effect until either party gives
the other 30 days' prior written notice of termination pursuant to paragraph 6 below." 



2.    Other Matters.


2.1    Except
as amended hereby, the Consulting Agreement shall remain in full force and effect. 


2.2    This
Second Amendment shall be binding on the parties and their respective successors and assigns. 


2.3    This
Second Amendment shall be governed and interpreted in accordance with the laws of the State of Delaware, without giving effect to any conflict of laws provisions. 






 

        IN
WITNESS WHEREOF, the undersigned have executed this Second Amendment as of the date first written above. 



	
 	
 	

CEPHALON, INC.
	

 	
 	

By:	
 	

 
	 	 	 	 	/s/  FRANK BALDINO, JR.      
 Name:  Frank Baldino, Jr., Ph.D.

Title:    Chairman and Chief Executive officer
	

 	
 	
MARTYN D. GREENACRE
	    	 	 	 	 
	

 	
 	

/s/  MARTYN D. GREENACRE      





2
#### Elrod *v.*Sutton.

No. 8786.

June 16, 1932.

Beck, P. J.

The motion for a new trial in this ease contains only the usual general grounds; and there being sufficient evidence to authorize the verdict, the court below did not err in refusing a new trial.

*Judgment affirmed.*

*Russell, G. J., and Atkinson, Hill and Gilbert, JJ., concur.*

*903
      *B. F. Whelchel, W. P. Whelchel,*and *B. P. Gaillard Jr.,*for plaintiff in error.

*Hammond Johnson, B. W. Smith Jr.,*and *Alex. M. Hitz,*contra.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-25-1999
<PERIOD-START>                             DEC-27-1998
<PERIOD-END>                               SEP-25-1999
<CASH>                                           3,286
<SECURITIES>                                         0
<RECEIVABLES>                                   62,735
<ALLOWANCES>                                     7,945
<INVENTORY>                                     28,616
<CURRENT-ASSETS>                                88,395
<PP&E>                                          97,038
<DEPRECIATION>                                  29,601
<TOTAL-ASSETS>                                 344,528
<CURRENT-LIABILITIES>                           72,433
<BONDS>                                        215,312
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            81
<OTHER-SE>                                      53,826
<TOTAL-LIABILITY-AND-EQUITY>                   344,528
<SALES>                                        220,103
<TOTAL-REVENUES>                               220,103
<CGS>                                          153,091
<TOTAL-COSTS>                                  153,091
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              15,019
<INCOME-PRETAX>                                  (659)
<INCOME-TAX>                                      (36)
<INCOME-CONTINUING>                              (695)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (695)
<EPS-BASIC>                                     (0.09)
<EPS-DILUTED>                                   (0.09)



</TABLE>
§ 556.660 Sulfamerazine. ( a ) [Reserved]
( b ) *Tolerances.* The tolerance for sulfamerazine is: ( 1 ) *Trout.* Edible tissues: Zero.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 520.2218 and 558.582 of this chapter.
[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2890 Vessel occlusion transducer. ( a ) *Identification.* A vessel occlusion transducer is a device used to provide an electrical signal corresponding to sounds produced in a partially occluded vessel. This device includes motion, sound, and ultrasonic transducers.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1175 Cholesterol (total) test system. ( a ) *Identification.* A cholesterol (total) test system is a device intended to measure cholesterol in plasma and serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2305, Jan. 14, 2000]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5550 Anesthetic gas mask. ( a ) *Identification.* An anesthetic gas mask is a device, usually made of conductive rubber, that is positioned over a patient's nose or mouth to direct anesthetic gases to the upper airway.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 41107, Sept. 17, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38795, July 25, 2001]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.3400 Device for sealing microsections. ( a ) *Identification.* A device for sealing microsections is an automated instrument used to seal stained cells and microsections for histological and cytological examination.
( b ) *Classification.* Class I (general controls). This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60589, Sept. 12, 1980, as amended at 54 FR 25044, June 12, 1989; 66 FR 38789, July 25, 2001]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7875 Thrombin time test. ( a ) *Identification.* A thrombin time test is a device used to measure fibrinogen concentration and detect fibrin or fibrinogen split products for the evaluation of bleeding disorders.
( b ) *Classification.* Class II (performance standards).
[45 FR 60628, Sept. 12, 1980]
**99.2**

 

**Form of Certification**

 

**CERTIFICATIONPURSUANT TO SECTION 906**

 

**OF THE SARBANES-OXLEYACT OF 2002**

 

In connectionwith the Quarterly Report on Form 10-Q of ebix.com, Inc. (the “Company”) forthe quarterly period ended September 30, 2002 as filed with the Securities andExchange Commission on the date hereof (the “Report”), I, Richard J. Baum,Chief Financial Officer of the Company, certify, pursuant to section 906 of theSarbanes-Oxley Act of 2002, that:

 

(1)                                  theReport fully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2)                                  theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
| By:                      | /s/ Richard  J. Baum |   |   |
|--------------------------|----------------------|--------|--------|
|                     |                 |
| Name:                    | Richard J.  Baum     |   |   |
|                     |                 |
| Chief  Financial Officer |                 |
|                     |                 |
| November 13,  2002       |                 |
|                          |                      |        |        |  |  |

 

----
§ 74.2151 D&C Brown No. 1. ( a ) *Identity.* The color additive D&C Brown No. 1 is a mixture of the sodium salts of 4[[5-[(dialkylphenyl)- azo]-2,4-dihydroxyphenyl]azo]-benzene sulfonic acid. The alkyl group is principally the methyl group.
( b ) *Specifications.* D&C Brown No. 1 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such other impurities may be avoided by good manufacturing practice: Sum of volatile matter (at 135 °C) and chlorides and sulfates (calculated as sodium salts), not more than 16 percent. Water-insoluble matter, not more than 0.2 percent. Sulfanilic acid, sodium salt, not more than 0.2 percent. Resorcinol, not more than 0.2 percent. Xylidines, not more than 0.2 percent. Disodium salt of 4[[5-[(4-sulfophenyl)-azo]-2,4-dihydroxyphenyl]azo] benzenesulfonic acid, not more than 3 percent. Monosodium salt of 4[[5-[(2,4-dimethyl-phenyl)azo] -2,4-dihydroxyphenyl]azo] benzenesulfonic acid, not less than 29 percent and not more than 39 percent. Monosodium salt of 4[[5-[(2,5-dimethyl-phenyl)azo] -2,4-dihydroxyphenyl]azo] benzenesulfonic acid, not less than 12 percent and not more than 17 percent. Monosodium salt of 4[[5-[(2,3-dimethyl-phenyl)azo] - 2,4-dihydroxyphenyl]azo] benzenesulfonic acid, not less than 6 percent and not more than 13 percent. Monosodium salt of 4[[5-[(2-ethylphenyl)-azo]-2,4-dihydroxyphenyl]-azo] benzenesulfonic acid, not less than 5 percent and not more than 12 percent. Monosodium salt of 4[[5-[(3,4-dimethyl-phenyl)azo] -2,4-dihydroxyphenyl]azo] benzenesulfonic acid, not less than 3 percent and not more than 9 percent. Monosodium salt of 4[[5-[(2,6-dimethyl-phenyl)azo] -2,4-dihydroxyphenyl]azo] benzenesulfonic acid, not less than 3 percent and not more than 8 percent. Monosodium salt of 4[[5-[(4-ethylphenyl) azo]-2,4-dihydroxyphenyl]-azo] benzenesulfonic acid, not less than 2 percent and not more than 8 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 84 percent.
( c ) *Uses and restrictions.* D&C Brown No. 1 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Brown No. 1 shall be certified in accordance with regulations in part 80 of this chapter.
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9100 Empty container for the collection and processing of blood and blood components. ( a ) *Identification.* An empty container for the collection and processing of blood and blood components is a device intended for medical purposes that is an empty plastic bag or plastic or glass bottle used to collect, store, or transfer blood and blood components for further processing.
( b ) *Classification.* Class II (performance standards).
[45 FR 60638, Sept. 12, 1980]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5830 Autotransfusion apparatus. ( a ) *Identification.* An autotransfusion apparatus is a device used to collect and reinfuse the blood lost by a patient due to surgery or trauma.
( b ) *Classification.* Class II (performance standards).